TEJ-KOHLI-FOUNDATION
21.2.2020 09:02:12 CET | Business Wire | Press release
The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005010/en/
The Tej Kohli Foundation continues to build its position as a multi-disciplinary global centre of focus for the development and advancement of an affordable, scalable and accessible ‘universal solution’ for preventing and eliminating corneal blindness. The World Health Organisation says that 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. Whilst approximately 75% of corneal disease is curable by corneal transplant, the costs of invasive surgery, and the many years of medicine needed to prevent rejection after surgery, makes this form of treatment entirely inaccessible to the majority of the people in the world who suffer from severe visual impairment or corneal blindness.
Tej Kohli co-founded the eponymous Foundation in 2005 alongside wife Wendy Kohli. He has previously spoken about funding life-changing corneal transplants in poor and underserved communities as being “like Schindler’s List, you do a few, then you just have to do more” (https://www.telegraph.co.uk/technology/2019/10/04/tej-kohli-indian-tech-billionaire-plans-turbocharge-britains/ ). In December 2019 the Tej Kohli Foundation announced that it had restored the sight of 5,736 blind people during the year (https://www.businesswire.com/news/home/20191219005417/en/5736-World%E2%80%99s-Poorest-People-Received-Gift-Sight ) and committed $14m of further funding to its Cornea Institute.
Tej Kohli is also an evangelist of the opportunities that can be derived from the chain reaction of technological progression and the impact that they can have on human life: https://www.spearswms.com/billionaire-philanthropist-tej-kohli-ai/ . The new Tej Kohli Foundation incubator hopes to back projects that can leverage this chain reaction of technological progression to develop and deliver new techniques and applications and game-changing innovations for improving access. The Foundation is seeking to incubate between one and three new projects initially, and welcomes funding applications from all fields of expertise. Projects must show that they can make a significant impact by 2035.
The Tej Kohli Foundation funded its first donor cornea implants at Niramaya Hospital in India in 2010. After funding thousands of corneal transplants, in 2015 the Tej Kohli Foundation substantially expanded its efforts to tackle corneal blindness in poor and underserved communities with the ambitious launch the Tej Kohli Cornea Institute in Hyderabad. Between January 2016 and November 2019 the Tej Kohli Cornea Institute welcomed more than 223,404 outpatients and completed more than 43,255 surgical procedures. The Tej Kohli Foundation has also pursued a ‘universal treatment’ for corneal blindness through its ‘Applied Research’ program, which is a longstanding scientific collaboration between researchers in Montreal Canada, and Moorfields Eye Hospital in the UK.
In January 2020 seed funding from the Tej Kohli Foundation was granted to two new research projects. The first project will focus on preventing corneal endothelial cell loss, which is usually permanent and is the leading reason for corneal transplantation worldwide. The second project will use novel drugs released by contact lenses to treat ocular surface pain and overcome the need for opioids when treating severe eye pain, which remains one of the unmet needs in Ophthalmology.
Eligible projects are invited to submit a 2-page project abstract as a PDF to: project2035@tejkohlifoundation.com . Submissions will be considered by the Tej Kohli Foundation on a case-by-case basis in direct collaboration with its global network of specialists.
Wendy Kohli, co-Founder of the Tej Kohli Foundation said:
“The YouTube channel of the Tej Kohli Foundation has many stories of individuals who have been cured of severe visual impairment or corneal blindness. But the overwhelming majority of those living needlessly with blindness still cannot afford or access treatment. It is only through major innovations borne from research, science, technology and enterprise that we can move toward a world where nobody is needlessly blind because of poverty.”
Tej Kohli, co-Founder of the Tej Kohli Foundation said:
“There are many innovations already in the pipeline that could one day offer affordable, scalable and accessible solutions for prevention and cure in the poor and underserved communities where corneal blindness is most pervasive. At the Tej Kohli Foundation we are interested in backing and funding new innovations and projects that will accelerate progress toward the goal of eliminating poverty-driven corneal blindness worldwide by 2035.”
About the Tej Kohli Foundation:
Website: http://www.tejkohlifoundation.com
YouTube: https://www.youtube.com/c/tejkohlifoundation
About Tej Kohli:
Profile: https://www.tejkohlifoundation.com/tej-kohli
Twitter: https://twitter.com/mrtejkohli
About Wendy Kohli:
Profile: https://www.tejkohlifoundation.com/wendy-kohli
View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005010/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom